Adverse reactions to anti-tuberculosis drugs in patients with pulmonary tuberculosis with concomitant diabetes mellitus

DOI: https://doi.org/10.29296/25877305-2020-07-07
Download full text PDF
Issue: 
7
Year: 
2020

Professor O. Komissarova(1, 2), MD; Professor R. Abdullaev(1), MD; S. Aleshina(1) (1)Central
Research Institute of Tuberculosis, Moscow (2)N.I. Pirogov Russian National Research Medical University,
Moscow

Adverse reactions to anti-tuberculosis drugs are more common in patients with pulmonary tuberculosis concurrent with diabetes mellitus (DM) than in those with tuberculosis without DM. A detailed analysis has shown that these are reactions, such as hepatotoxic, allergic, and neurotoxic ones.
Keywords: 
phthisiology
tuberculosis
diabetes mellitus
adverse reactions
anti-tuberculosis drugs

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Dedov I.I., Shestakovoj M.V., Majorova A.Ju. Algoritmy spetsializirovannoj meditsinskoj pomoschi bol'nym saharnym diabetom – 9-j vypusk. Saharnyj diabet. 2019; 22 (S1): 211 [Dedov I.I., Shestakova M.V., Mayorov A.Yu. Standards of specialized diabetes care. 9th Edition. Diabetes mellitus. 2019; 22 (S1): 211 (in Russ.)]. DOI: 10.14341/DM221S1.
  2. World Health Organization, Global tuberculosis report 2018.WHO/CDS/TB/2018.20. http://www.who.int
  3. Ronacher K., van Crevel R., Critchley J. et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms. Chest. 2017; 152 (1): 17480. DOI: 10.1016/j.chest.2017.02.032.
  4. Komissarova O.G., Abdullaev R.Ju., Mihajlovskij A.M. Saharnyj diabet kak faktor riska razvitija tuberkuleza: patofiziologicheskie aspekty. Med al'jans. 2017; 3: 28–34 [Komissarova O., Abdullaev R., Michaylovskiy A. Diabetes mellitus as a risk factor for tuberculosis: pathophysiological aspects. Med alyance. 2017; 3: 28–34 (in Russ.)].
  5. Jeon C., Murray M. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008; 5 (7): e152. DOI: 10.1371/journal.pmed.0050152.
  6. Komissarova O.G., Abdullaev R.Ju., Konjaeva O.O. i dr. Rasprostranennost', klinicheskie projavlenija i effektivnost' lechenija tuberkuleza u bol'nyh saharnym diabetom. Vrach. 2017; 28 (2): 24–8 [Komissarova O., Abdullaev R., Konyaeva O., et al. The prevalence and clinical manifestations of tuberculosis and the efficiency of its treatment in patients with diabetes mellitus. Vrach. 2017; 28 (2): 24–8 (in Russ.)].
  7. Komissarova O.G., Abdullaev R.Ju., Aleshina S.V. i dr. Oslozhnenija saharnogo diabeta pri ego sochetanii s tuberkulezom legkih. Vrach. 2019; 30 (7): 38–41 [Komissarova O., Abdullaev R., Aleshina S. et al. Complications of diabetes mellitus in its concurrence with pulmonary tuberculosis. Vrach. 2019; 30 (7): 38–41 (in Russ.)]. https://doi.org/10.29296/25877305-2019-07-07
  8. Tihonova L.Ju., Sokolova V.V., Tarasjuk I.A. i dr. Opyt primenenija preparata Bedakvilin u bol'nyh tuberkulezom s mnozhestvennoj lekarstvennoj ustojchivost'ju vozbuditelja v Amurskoj oblasti. Tuberkulez i bolezni legkih. 2018; 96 (6): 45–50 [Tikhonova L.Yu., Sokolova V.V., Tarasyuk I.A., et al. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases. 2018; 96 (6): 45–50 (in Russ.)]. DOI: 10.21292/2075-1230-2018-96-6-45-50
  9. Golubchikov P.N., Kruk E.A., Mishustin S.P. i dr. Opyt lechenija bol'nyh tuberkulezom c shirokoj lekarstvennoj ustojchivost'ju vozbuditelja, v tom chisle s dlitel'nym primeneniem bedakvilina, v Tomskoj oblasti: neposredstvennye i otdalennye rezul'taty. Tuberkulez i bolezni legkih. 2019; 97 (8): 38–45 [Golubchikov P.N., Kruk E.A., Mishustin S.P. et al. Experience of treating extensive drug resistant tuberculosis patients including continuous use of bedaquiline, in Tomsk Region: immediate and postponed results. Tuberculosis and Lung Diseases. 2019; 97 (8): 38–45 (in Russ.)]. DOI: 10.21292/2075-1230-2019-97-8-38-45